CD271 (NGFR) is a neurotrophin receptor that belongs to the tumor necrosis receptor (TNFR) family. Upon ligand binding, CD271 can mediate either survival or cell death. While the role of CD271 as a marker of tumor-initiating cells is still a matter of debate, its role in melanoma progression has been well documented. Moreover, CD271 has been shown to be upregulated after exposure to both chemotherapy and targeted therapy. In this study, we demonstrate that activation of CD271 by a short β-amyloid-derived peptide (Aβ(25-35)) in combination with either chemotherapy or MAPK inhibitors induces apoptosis in 2D and 3D cultures of 8 melanoma cell lines. This combinatorial treatment significantly reduced metastasis in a zebrafish xenograft model and led to significantly decreased tumor volume in mice. Administration of Aβ(25-35) in ex vivo tumors from immunotherapy- and targeted therapy-resistant patients significantly reduced proliferation of melanoma cells, showing that activation of CD271 can overcome drug resistance. Aβ(25-35) was specific to CD271-expressing cells and induced CD271 cleavage and phosphorylation of JNK (pJNK). The direct protein-protein interaction of pJNK with CD271 led to PARP1 cleavage, p53 and caspase activation, and pJNK-dependent cell death. Aβ(25-35) also mediated mitochondrial reactive oxygen species (mROS) accumulation, which induced CD271 overexpression. Finally, CD271 upregulation inhibited mROS production, revealing the presence of a negative feedback loop in mROS regulation. These results indicate that targeting CD271 can activate cell death pathways to inhibit melanoma progression and potentially overcome resistance to targeted therapy.

Specific activation of the CD271 intracellular domain in combination with chemotherapy or targeted therapy inhibits melanoma progression / Saltari, Annalisa; Dzung, Andreas; Quadri, Marika; Tiso, Natascia; Facchinello, Nicola; Hernandez-Barranco, Alberto; Garcia-Silva, Susana; Nogués, Laura; Stoffel, Corinne Isabelle; Cheng, Phil F; Turko, Patrick; Eichhoff, Ossia M; Truzzi, Francesca; Marconi, Alessandra; Pincelli, Carlo; Peinado, Héctor; Dummer, Reinhard; Levesque, Mitchell P. - In: CANCER RESEARCH. - ISSN 0008-5472. - 81:23(2021), pp. 6044-6057. [10.1158/0008-5472.CAN-21-0117]

Specific activation of the CD271 intracellular domain in combination with chemotherapy or targeted therapy inhibits melanoma progression

Saltari, Annalisa;Quadri, Marika;Truzzi, Francesca;Marconi, Alessandra;Pincelli, Carlo;
2021-01-01

Abstract

CD271 (NGFR) is a neurotrophin receptor that belongs to the tumor necrosis receptor (TNFR) family. Upon ligand binding, CD271 can mediate either survival or cell death. While the role of CD271 as a marker of tumor-initiating cells is still a matter of debate, its role in melanoma progression has been well documented. Moreover, CD271 has been shown to be upregulated after exposure to both chemotherapy and targeted therapy. In this study, we demonstrate that activation of CD271 by a short β-amyloid-derived peptide (Aβ(25-35)) in combination with either chemotherapy or MAPK inhibitors induces apoptosis in 2D and 3D cultures of 8 melanoma cell lines. This combinatorial treatment significantly reduced metastasis in a zebrafish xenograft model and led to significantly decreased tumor volume in mice. Administration of Aβ(25-35) in ex vivo tumors from immunotherapy- and targeted therapy-resistant patients significantly reduced proliferation of melanoma cells, showing that activation of CD271 can overcome drug resistance. Aβ(25-35) was specific to CD271-expressing cells and induced CD271 cleavage and phosphorylation of JNK (pJNK). The direct protein-protein interaction of pJNK with CD271 led to PARP1 cleavage, p53 and caspase activation, and pJNK-dependent cell death. Aβ(25-35) also mediated mitochondrial reactive oxygen species (mROS) accumulation, which induced CD271 overexpression. Finally, CD271 upregulation inhibited mROS production, revealing the presence of a negative feedback loop in mROS regulation. These results indicate that targeting CD271 can activate cell death pathways to inhibit melanoma progression and potentially overcome resistance to targeted therapy.
81
23
6044
6057
Specific activation of the CD271 intracellular domain in combination with chemotherapy or targeted therapy inhibits melanoma progression / Saltari, Annalisa; Dzung, Andreas; Quadri, Marika; Tiso, Natascia; Facchinello, Nicola; Hernandez-Barranco, Alberto; Garcia-Silva, Susana; Nogués, Laura; Stoffel, Corinne Isabelle; Cheng, Phil F; Turko, Patrick; Eichhoff, Ossia M; Truzzi, Francesca; Marconi, Alessandra; Pincelli, Carlo; Peinado, Héctor; Dummer, Reinhard; Levesque, Mitchell P. - In: CANCER RESEARCH. - ISSN 0008-5472. - 81:23(2021), pp. 6044-6057. [10.1158/0008-5472.CAN-21-0117]
Saltari, Annalisa; Dzung, Andreas; Quadri, Marika; Tiso, Natascia; Facchinello, Nicola; Hernandez-Barranco, Alberto; Garcia-Silva, Susana; Nogués, Laura; Stoffel, Corinne Isabelle; Cheng, Phil F; Turko, Patrick; Eichhoff, Ossia M; Truzzi, Francesca; Marconi, Alessandra; Pincelli, Carlo; Peinado, Héctor; Dummer, Reinhard; Levesque, Mitchell P
File in questo prodotto:
File Dimensione Formato  
Manuscript R1_.pdf

Open access

Descrizione: articolo principale
Tipologia: Versione originale dell'autore proposta per la pubblicazione
Dimensione 1.11 MB
Formato Adobe PDF
1.11 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1255846
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 3
social impact